| Literature DB >> 33854322 |
Nawaphan Taengsakul1, Thaweechai Saiwongse1, Orattha Sakornwattananon1, Pattraporn Kreesaeng1, Nuttavut Kantathavorn2,3.
Abstract
PURPOSE: To determine the incidence and risk factor of postoperative venous thromboembolism (VTE) in Thai populations and to evaluate morbidity, mortality, bleeding complications and the benefit of thromboprophylaxis in real-world practice. PATIENTS AND METHODS: We performed a retrospective, single-center, cohort study of patients from all age groups who underwent elective open or laparoscopic major abdomino-pelvic surgery between January 2008 and December 2018 at Chulabhorn Hospital, Bangkok, Thailand. We collected general medical information and specific data based on items from the Caprini risk scoring system.Entities:
Keywords: Thailand; abdomino-pelvic surgery; deep vein thrombosis; postoperative venous thromboembolism; thromboprophylaxis
Mesh:
Substances:
Year: 2021 PMID: 33854322 PMCID: PMC8041647 DOI: 10.2147/VHRM.S304187
Source DB: PubMed Journal: Vasc Health Risk Manag ISSN: 1176-6344
Demographic Characteristics of Patients
| Characteristics | Number of Patients (%) |
|---|---|
| Age | Mean: 54.59 ± 13.27 |
| 20–59 yrs. | 1646 (66.9%) |
| >60 yrs. | 816 (33.1%) |
| Sex | |
| - Male | 742 (30.1%) |
| - Female | 1720 (69.9%) |
| Body mass index | Mean = 23.49±4.29 |
| <30 kg/m2 | 2261 (91.8%) |
| ≥30 kg/m2 | 179 (7.3%) |
| Malignant disease | 1501 (61%) |
| History of VTE | |
| - None | 2437 (99%) |
| - DVT | 18 (0.7%) |
| - PE | 5 (0.2%) |
| - DVT + PE | 2 (0.1%) |
| Underlying disease | |
| - Diabetes mellitus | 341 (13.9%) |
| - Hypertension | 776 (31.5%) |
| - Chronic kidney disease | 50 (2%) |
| - Cerebrovascular disease | 46 (1.9%) |
| - Ischemic heart disease | 33 (1.3%) |
| Smoking | 149 (6%) |
| Current medication | |
| - Antiplatelet | 102 (4.1%) |
| - Anticoagulant | 29 (2.1%) |
| - Oral contraceptive pill | 27 (1.1%) |
| - Hormone therapy | 79 (3.2%) |
| - Steroids use | 14 (0.6%) |
| TNM staging | |
| - Benign and Stage 0 | 1029 (41.8%) |
| - Stage 1 | 405 (16.5%) |
| - Stage 2 | 269 (10.9%) |
| - Stage 3 | 426 (17.3%) |
| - Stage 4 | 333 (13.5%) |
| Operative position | |
| - Supine | 1511 (61.4%) |
| - Lithotomy | 923 (37.5%) |
| Operative time | 2.37 ± 1.75 |
| - <3 hrs. | 1825 (74.1%) |
| - ≥3hrs. | 622 (25.3%) |
| Laparoscopic surgery | 721 (29.3%) |
| Immobilization | 2.05 ± 1.54 |
| <3 days | 1702 (69.1%) |
| ≥3 days | 740 (30.1%) |
Abbreviations: VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; INR, international normalized ratio; ACCP, American College of Chest Physicians.
Factors Influencing the Increase and Reduction in VTE Events
| Factor | VTE (n=12) | Non-VTE (n=2450) | Risk Ratio (95%Cl) | P-value |
|---|---|---|---|---|
| History of PE | 2 (16.7%) | 3 (0.1%) | 98.28 (28.47, 339.26) | <0.001 |
| History of DVT | 1 (8.3%) | 17 (0.7%) | 12.34 (1.68, 90.65) | 0.002 |
| Anticoagulant use | 2 (16.7%) | 27 (1.1%) | 16.78 (3.84, 73.22) | <0.001 |
| High risk in ACCP guideline | 11 (91.7%) | 1439 (58.7%) | 7.68 (0.99, 59.37) | 0.021 |
| Endometrial cancer | 2 (16.7%) | 75 (3.1%) | 6.2 (1.38, 27.79) | 0.007 |
| Obesity (BMI>30kg/m2) | 3 (25%) | 181 (7.4%) | 4.13 (1.13, 15.11) | 0.021 |
| Preoperative Chemotherapy | 5 (41.7%) | 431 (17.6%) | 3.32 (1.06, 10.41) | 0.029 |
| TNM Stage 4 | 4 (33.3%) | 329 (13.4%) | 3.2 (0.97, 10.56) | 0.044 |
| Postoperative chemotherapy | 7 (58.3%) | 765 (31.2%) | 3.06 (0.98, 9.63) | 0.044 |
| BMI<30 | 8 (66.7%) | 2247 (91.7%) | 0.18 (0.06, 0.6) | 0.002 |
| Benign disease | 1 (8.3%) | 1028 (42%) | 0.13 (0.02, 0.98) | 0.019 |
| None of VTE history | 9 (75%) | 2428 (99.1%) | 0.03 (0.01, 0.11) | <0.001 |
Abbreviations: VTE, venous thromboembolism; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; ACCP, American College of Chest Physicians.
Figure 1Percentage of patients undergoing each prophylaxis method according to adherence to ACCP guidelines.
Figure 2Comparison of type of surgery adherence to with ACCP guidelines.
Figure 3ACCP classification categories in our population and incidence of VTE in each of classification.
Figure 4Overall survival between the VTE and non-VTE groups.
Multivariate Analysis of Mortality from VTE and with Adherence to ACCP Guidelines
| Adjusted HR (95%Cl) | P-value | |
|---|---|---|
| VTE | 3.26 (1.04, 10.19) | 0.042 |
| Following ACCP | 0.53 (0.32, 0.88) | 0.014 |
Abbreviations: VTE, venous thromboembolism; HR, hazard ratio; CI, confidence interval; ACCP, American College of Chest Physicians.